secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyra Therapeutics, Inc. (LYRA)
CIK:        0001327273
Form:       8-K
Filed at:   2023-08-08T23:59:59+00:00
Accession:  0000950170-23-039769
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyra Therapeutics Q2 net loss $15.6M; cash $116.2M after $46.7M placement
-------------------------------------------------------------------------

- Cash and investments $116.2M at June 30, 2023, up from $82.7M at March 31, 2023.
- Net loss $15.6M for Q2 2023 vs $14.4M in Q2 2022; R&D expense flat at $10.8M.
- ENLIGHTEN I Phase 3 enrollment completion expected in weeks; data 1H 2024.
- BEACON Phase 2 topline results for LYR-220 now expected September 2023.
- Private placement closed May 31, 2023 yielded net proceeds of $46.7M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1327273/000095017023039769/0000950170-23-039769-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1327273/000095017023039769/lyra-20230808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-039769

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer